Claudio Tiribelli

From WikiProjectMed
Jump to navigation Jump to search

Claudio Tiribelli
Born (1946-10-06) 6 October 1946 (age 77)
Venice, Italy
Children1 son
Scientific career
InstitutionsUniversity of Trieste
Fondazione Italiana Fegato - Italian Liver Foundation

Claudio Tiribelli (born 6 October 1946) is an Italian hepatologist best known for his studies on bilirubin and Kernicterus, a bilirubin-induced neurological condition.[1]

Scientific activity

Since very early in his career, Tiribelli was fascinated by bilirubin.[2] Expanding upon his research activity and expertise, he founded Bilimetrix together with Richard Wennberg. Bilimetrix developed the first point-of-care device for measuring bilirubin in newborns. Early detection of harmful bilirubin levels would prevent neonatal jaundice and allow the newborns to receive timely and proper treatment.

Due to his clinical activity and research interests, he is active in translational activity in several liver disorders as fatty liver disease and hepatocellular carcinoma. Together with his longstanding research associate Stefano Bellentani, he designed and performed the Dionysus Study,[3][4] the first project exploring the prevalence and incidence of liver diseases in the general population.

Tiribelli is coordinating a large group of researchers (including postdoctoral fellows, PhD candidates, and senior researchers) located in the hub lab at the Italian Liver Foundation in Trieste. The international programs Claudio is coordinating forces him to cross the Equator 14 times in 2019 (before the COVID pandemic).

Scientific publications

Claudio has over 350 scientific publications,[5] some of his most cited works are:

  • "Bilirubin-Induced Neurologic Damage — Mechanisms and Management Approaches"[1]
  • "Prevalence of chronic liver diseases in the general population of Northern Italy: The Dionysos study"[4]
  • "Prevalence And Risk Factors For Hepatic Steatosis In Northern Italy"[3]
  • "The fatty liver index: a simple and accurate predictor of hepatic steatosis in the general population"[6]
  • "Molecular basis and mechanisms of progression of nonalcoholic steatohepatitis (NASH)"[7]
  • "Intestinal Integrity, the Microbiome and Inflammation"[8]

References

  1. ^ a b Watchko, Jon F.; Tiribelli, Claudio (21 November 2013). Ingelfinger, Julie R. (ed.). "Bilirubin-Induced Neurologic Damage — Mechanisms and Management Approaches". New England Journal of Medicine. 369 (21): 2021–2030. doi:10.1056/NEJMra1308124. ISSN 0028-4793. PMID 24256380.
  2. ^ "claudio tiribelli bilirubin - Search Results - PubMed". PubMed. Retrieved 11 August 2021.
  3. ^ a b Bellentani, Stefano; Saccoccio, Gioconda; Masutti, Flora; Crocè, Lory S.; Brandi, Giovanni; Sasso, Franco; Cristanini, Giovanni; Tiribelli, Claudio (18 January 2000). "Prevalence of and Risk Factors for Hepatic Steatosis in Northern Italy". Annals of Internal Medicine. 132 (2): 112–117. doi:10.7326/0003-4819-132-2-200001180-00004. ISSN 0003-4819. PMID 10644271. S2CID 25141053.
  4. ^ a b Bellentani, Stefano; Tiribelli, Claudio; Saccoccio, Gioconda; Sodde, Marino; Fratti, Nicoletta; De Martin, Christina; Christianini, Giovanni (1 December 1994). "Prevalence of chronic liver disease in the general population of northern Italy: The dionysos study". Hepatology. 20 (6): 1442–1449. doi:10.1002/hep.1840200611. PMID 7982643. S2CID 9045590.
  5. ^ "tiribelli c - Search Results - PubMed". PubMed. Archived from the original on 1 May 2021. Retrieved 29 July 2021.
  6. ^ Bedogni, Giorgio; Bellentani, Stefano; Miglioli, Lucia; Masutti, Flora; Passalacqua, Marilena; Castiglione, Anna; Tiribelli, Claudio (2 November 2006). "The Fatty Liver Index: a simple and accurate predictor of hepatic steatosis in the general population". BMC Gastroenterology. 6 (1): 33. doi:10.1186/1471-230X-6-33. ISSN 1471-230X. PMC 1636651. PMID 17081293.
  7. ^ Marra, Fabio; Gastaldelli, Amalia; Svegliati Baroni, Gianluca; Tell, Gianluca; Tiribelli, Claudio (22 January 2008). "Molecular basis and mechanisms of progression of non-alcoholic steatohepatitis". Trends in Molecular Medicine. 14 (2): 72–81. doi:10.1016/j.molmed.2007.12.003. PMID 18218340.
  8. ^ Vítek, Libor; Tiribelli, Claudio (13 August 2020). Phimister, Elizabeth G. (ed.). "Bilirubin, Intestinal Integrity, the Microbiome, and Inflammation". New England Journal of Medicine. 383 (7): 684–686. doi:10.1056/NEJMcibr2013250. ISSN 0028-4793. PMID 32786195. S2CID 221126495.

 

Retrieved from "https://mdwiki.org/wiki/Claudio_Tiribelli"